Trial Profile
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy and Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Ontuxizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms MICRO
- Sponsors Morphotek
- 30 Oct 2017 Primary endpoint (Progression-free survival) has not been met, according to the results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 30 Oct 2017 Status changed from active no longer recruiting to discontinued, according to the results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 30 Oct 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research